scholarly article | Q13442814 |
P2093 | author name string | Scott Vuocolo | |
Stephen E Goldstone | |||
P2860 | cites work | Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review | Q22306450 |
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males | Q24614644 | ||
Trends in the incidence of invasive and in situ vulvar carcinoma | Q24825208 | ||
Global cancer statistics, 2002 | Q27860562 | ||
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine | Q28255537 | ||
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women | Q28271727 | ||
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 | ||
Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis | Q28305321 | ||
Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
Classification of papillomaviruses | Q29618731 | ||
Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia | Q31035514 | ||
External genital warts: diagnosis, treatment, and prevention. | Q31112715 | ||
Recurrent respiratory papillomatosis in children: masquerader of common respiratory diseases | Q33154439 | ||
Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management | Q33259401 | ||
Human papillomavirus-related disease in men: not just a women's issue | Q33855416 | ||
Chapter 1: HPV in the etiology of human cancer | Q34562937 | ||
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection | Q34562942 | ||
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis | Q34642665 | ||
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students | Q34705438 | ||
Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. | Q34801294 | ||
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents | Q34910428 | ||
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men | Q34910475 | ||
Human papillomavirus vaccines and prevention of cervical cancer | Q35640262 | ||
Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis | Q35746826 | ||
The costs of treating external genital warts in England and Wales: a treatment pattern analysis | Q35861590 | ||
Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States | Q35988721 | ||
Worldwide burden of gynaecological cancer: the size of the problem | Q36344510 | ||
Prevention of recurrent respiratory papillomatosis: role of HPV vaccination | Q36555070 | ||
Chapter 2: The burden of HPV-related cancers | Q36584354 | ||
Chapter 15: HPV vaccine use in the developing world | Q36584364 | ||
Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease | Q36584416 | ||
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 | ||
Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis | Q36670753 | ||
The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus | Q36717732 | ||
The economic burden of noncervical human papillomavirus disease in the United States | Q36740006 | ||
Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. | Q37220744 | ||
Human papillomavirus prevalence and type distribution in penile carcinoma | Q37586655 | ||
Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications | Q37622609 | ||
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine | Q37642538 | ||
HPV vaccine and males: issues and challenges | Q37686833 | ||
Post-licensure monitoring of HPV vaccine in the United States | Q37699644 | ||
Pathology and epidemiology of HPV infection in females | Q37715406 | ||
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. | Q37745678 | ||
Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. | Q37850481 | ||
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years | Q38383523 | ||
International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas | Q38503187 | ||
Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study | Q39700791 | ||
Burden of cervical cancer in Europe: estimates for 2004. | Q40232407 | ||
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines | Q40430523 | ||
Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. | Q40448304 | ||
Prognostic significance of human papillomavirus DNA in vulvar carcinoma | Q40510041 | ||
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women | Q43655015 | ||
Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. | Q44028516 | ||
The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay | Q44995543 | ||
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Q45206974 | ||
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine | Q45212845 | ||
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine | Q45404033 | ||
Natural history of vaginal intraepithelial neoplasia | Q45736749 | ||
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia | Q46421186 | ||
Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. | Q46645214 | ||
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection | Q46654947 | ||
Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. | Q46870430 | ||
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication | Q47860026 | ||
The health and economic burden of genital warts in a set of private health plans in the United States | Q47887573 | ||
Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. | Q48718586 | ||
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. | Q50627829 | ||
The psychosocial impact of human papillomavirus infection: implications for health care providers. | Q51114247 | ||
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. | Q51257523 | ||
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. | Q54495496 | ||
Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. | Q54569323 | ||
Oropharyngeal carcinoma related to human papillomavirus | Q56532842 | ||
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions | Q56770293 | ||
P433 | issue | 4 | |
P304 | page(s) | 395-406 | |
P577 | publication date | 2012-04-01 | |
P1433 | published in | Expert Review of Vaccines | Q15756339 |
P1476 | title | A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. | |
P478 | volume | 11 |